

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
178464	20/WM/0032	269685	Correlating Dynamic chest radiography measurements with lung function in patients with asthma, COPD and ILD: a pilot study	Yes	10/12/2020	0	21	21	07/03/2019	19/11/2020	17/02/2020	17/11/2020	19/11/2020	Please Select...	04/12/2020			Please Select...
178465	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	Yes	12/01/2021	0	36	36	28/07/2020	07/12/2020	10/09/2020	04/12/2020	07/12/2020	Please Select...	08/12/2020			Please Select...
178466	20/EE/0118	283014	COG-UK HOCl study	Yes	13/11/2020	0	7	7	09/04/2020	06/11/2020	15/06/2020	06/11/2020	06/11/2020	Please Select...	09/11/2020			Please Select...
178467	20/WA/0058	268723	Procalcitonin and NEWS2 evaluation for Timely identification of Sepsis and Optimal use of antibiotics in the Emergency Department	Yes	23/02/2021	119	36	155	31/07/2020	21/09/2020	22/07/2020	10/12/2020	18/01/2021	Please Select...	18/02/2021			Please Select...
178468	20/LO/0021	274860	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	No		1			21/02/2020	03/02/2021	21/02/2020	04/02/2021	04/02/2021	Please Select...	05/02/2021	I - Rare diseases	This is an extension study, there is a patient to recruit but due to COVID this has been on hold. This study is now open	Neither
178475	20/WM/0250	285588	A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alafenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed	Yes	19/03/2021	5	17	22	03/07/2020	25/02/2021	02/12/2020	02/03/2021	02/03/2021	Please Select...	10/03/2021			Please Select...
178476	20/LO/0348	278100	A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 with treatment-naïve diabetic retinopathy.	No		0			22/02/2020	23/03/2021	14/09/2020	22/03/2021	23/03/2021	Please Select...	23/03/2021			Please Select...
178477	20/NW/0472	288505	A prospective feasibility trial, to facilitate increases in physical activity and reduce sedentary behaviour in patients after bariatric surgery	Yes	15/03/2021	5	41	46	18/11/2020	28/01/2021	21/12/2020	28/01/2021	02/02/2021	Please Select...	02/02/2021			Please Select...
178478	20?SW/0138	234270	DEFINE-FMS	Yes	04/05/2021	6	71	77	18/11/2020	16/02/2021	05/11/2020	11/02/2021	22/02/2021	Please Select...	11/03/2021	J - Other	Delays due to COVID	Neither